YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD transgenic mouse model with five familial AD mutations (5XFAD).
Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Amyloid-β
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。